OmniActive Launches Fenugreek-Shatavari Complex for Menopause Support

OmniActive Health Technologies has launched Fenavari, a complex of fenugreek (Trigonella foenum-graecum) and shatavari (Asparagus racemosus) extracts, for menopause support.

In a randomized, double-blind, placebo-controlled study published in Women’s Health Reports, the ingredient was shown to support seven symptoms associated with midlife hormonal changes, including fewer instances of hot flashes and night sweats; maintenance of healthy hormonal balance; and support for sleep, quality, mood, occasional feelings of anxiety, and sexual wellness.  

OmniActive’s proprietary consumer research, which included surveys of more than 500 women over the age of 45, found that 61% experience hot flashes, 62% report trouble sleeping, 57% experience night sweats, and 51% experience mood swings, while 63% turn to natural remedies and over-the-counter products for relief.

“Shatavari may be trending, but both shatavari and fenugreek have a long history of use in women’s health,” said Keya Shah, senior director of women’s health for OmniActive. “Fenavari harnesses the power of both botanicals in one clinically studied, integrated extract, giving brands and doctors a natural solution for the full menopausal journey. In fact, we recently conducted a survey and found nine out of 10 healthcare professionals said they’d recommend Fenavari to their patients to help address symptoms associated with hormonal changes during menopause.”

Clinical Study Details

In the clinical study, 138 women between the ages of 40 and 60 showed significant improvements over placebo, at doses of either 300 or 500 mg by day 14 of the treatment period.

By the end of the study, Fenavari was associated with:

• Up to 52% reduction in hot flashes at 300 mg and up to 61% at 500 mg
• Up to 47% reduction in night sweats at 300 mg and up to 51% at 500 mg
• Subjective improvements in sleep quality, mood, and occasional feelings of anxiety
• Subjective improvements in sexual wellness measures
• Significant increases in estradiol and decreases in follicle-stimulating hormone (FSH), a favorable change for overall hormonal balance.

Fenavari was developed after mechanism-of-action research on both botanicals. OmniActive employed AI-based validation to support the MOA and synergistic effects of the two botanicals, setting a foundation for clinical research.

“Fenavari utilizes the distinctive phytochemical profiles of fenugreek and shatavari, extracted through our proprietary integrated actives technology to provide a highly bioactive extract standardized to 6% shatavarin IV and 4% protodioscin, validated using high-performance liquid chromatography (HPLC),” said Abhijeet Morde, vice president of early discovery and translation science at OmniActive. “This integration enhances their complementary phytoestrogenic and adaptogenic properties, allowing for a more comprehensive approach to wellness for women entering their midlife and beyond. We remain committed to advancing our clinical research program for Fenavari in order to further substantiate its scientific foundation.”

The ingredient is manufactured using green solvents and is hormone- and soy-free. It will be available to formulators later this year.